XLV240823C154000
- 0.74
- +0.28+60.87%
The Health Care Select Sector SPDR® Fund Newsroom
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Barclays Remains a Buy on Eli Lilly & Co (LLY)
Eli Lilly Analyst Ratings
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Mizuho Adjusts Price Target on UnitedHealth Group to $650 From $560, Maintains Outperform Rating
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Guggenheim Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,030
RBC Capital Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Raises Target Price to $515
RBC Capital Reaffirms Their Buy Rating on Intuitive Surgical (ISRG)
Medtronic Upgraded at UBS on Diabetes Turnaround
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $381
Jefferies Adjusts Merck & Company Price Target to $147 From $150
HSBC Adjusts Price Target on Eli Lilly and Co. to $1,150 From $1,100, Maintains Buy Rating
Eli Lilly Analyst Ratings
Daiwa Securities Adjusts Price Target on Eli Lilly and Co. to $940 From $800, Maintains Outperform Rating
Berenberg Bank Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,050
Berenberg Bank Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
DBS Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,060
Leerink Partners Maintains Johnson & Johnson(JNJ.US) With Buy Rating
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $150